Development of a sensitive, accurate and robust liquid chromatography/mass spectrometric method for profiling of angiotensin peptides in plasma and its application for atherosclerotic mice

Journal of Chromatography A

Volumn 1393, Issue , 2015, Pages 37-46

  Olkowicz, Mariola ^a,b   Radulska, Adrianna ^a   Suraj, Joanna ^c,d   Kij, Agnieszka ^d   Walczak, Maria ^c,d   Chlopicki, Stefan ^c,d   Smolenski, Ryszard T ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b POZNA UNIVERSITY OF LIFE SCIENCES   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Angiotensins; Atherosclerotic mice; High resolution mass spectrometry; Renin angiotensin system; Targeted quantitative proteomics

Indexed keywords

MAMMALS; MASS SPECTROMETRY; PEPTIDES; PROTEOMICS;

ANGIOTENSINS; ATHEROSCLEROTIC MICE; HIGH RESOLUTION MASS SPECTROMETRY; QUANTITATIVE PROTEOMICS; RENIN-ANGIOTENSIN SYSTEM;

LIQUID CHROMATOGRAPHY;

ACLERASTIDE; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II [3-8]; ANGIOTENSIN III; APOLIPOPROTEIN E; DIPEPTIDYL CARBOXYPEPTIDASE; LOW DENSITY LIPOPROTEIN RECEPTOR; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN I (1-7); PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETER; MASS SPECTROMETRY; MEASUREMENT ACCURACY; MEASUREMENT PRECISION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FOLDING; PROTEIN METABOLISM; SENSITIVITY ANALYSIS; ANIMAL; BLOOD; C57BL MOUSE; GENETICS; KNOCKOUT MOUSE; PROCEDURES;

MUS;

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN III; ANGIOTENSINS; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CHROMATOGRAPHY, LIQUID; MASS SPECTROMETRY; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; RECEPTORS, LDL;

EID: 84926526543     PISSN: 00219673     EISSN: 18733778     Source Type: Journal    
DOI: 10.1016/j.chroma.2015.03.012     Document Type: Article

References (42)

1. Kim S., Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol. Rev. 2000, 52:11-34.
2. Mehta P.K., Griendling K.K. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell. Physiol. 2007, 292:C82-C97.
3. Mazzolai L., Pedrazzini T., Nicoud F., Gabbiani G., Brunner H.R., Nussberger J. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension 2000, 35:985-991.
4. Weiss D., Kools J.J., Taylor W.R. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001, 103:448-454.
5. Reudelhuber T.L. The renin-angiotensin system: peptides and enzymes beyond angiotensin II. Curr. Opin. Nephrol. Hypertens. 2005, 14:155-159.
6. Nguyen Dinh Cat A., Touyz R.M. A new look at the renin-angiotensin system - focusing on the vascular system. Peptides 2011, 32:2141-2150.
7. Kaschina E., Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press. 2003, 12:70-88.
8. Tesanovic S., Vinh A., Gaspari T.A., Casley D., Widdop R.E. Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1606-1613.
9. Montezano A.C., Nguyen Dinh Cat A., Rios F.J., Touyz R.M. Angiotensin II and vascular injury. Curr. Hypertens. Rep. 2014, 16:431.
10. Iwai M., Horiuchi M. Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hypertens. Res. 2009, 32:533-536.
11. Bohm M. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?. Am. J. Cardiol. 2007, 100:38j-44j.
12. Wei C.C., Tian B., Perry G., Meng Q.C., Chen Y.F., Oparil S., Dell'Italia L.J. Differential ANG II generation in plasma and tissue of mice with decreased expression of the ACE gene. Am. J. Physiol. Heart Circ. Physiol. 2002, 282:H2254-H2258.
13. Daugherty A., Rateri D.L., Lu H., Inagami T., Cassis L.A. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation 2004, 110:3849-3857.
14. Naik G.O., Moe G.W. Simultaneous separation of angiotensin and endothelin peptide families by high-performance liquid chromatography: application to the specific radioimmunoassay measurement of angiotensin II or endothelin-1 from tissue. J. Chromatogr. A 2000, 870:349-361.
15. Naik G.O., Moe G.W., Armstrong P.W. Specific and non-specific measurements of tissue angiotensin II cascade members. J. Pharm. Biomed. Anal. 2001, 24:947-955.
16. Kitteringham N.R., Jenkins R.E., Lane C.S., Elliott V.L., Park B.K. Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J. Chromatogr. B 2009, 877:1229-1239.
17. Kaufmann A., Butcher P., Maden K., Walker S., Widmer M. Quantitative and confirmative performance of liquid chromatography coupled to high-resolution mass spectrometry compared to tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2011, 25:979-992.
18. Werner C., Baumhakel M., Teo K.K., Schmieder R., Mann J., Unger T., Yusuf S., Bohm M. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin. Res. Cardiol. 2008, 97:418-431.
19. Henry H., Sobhi H.R., Scheibner O., Bromirski M., Nimkar S.B., Rochat B. Comparison between a high-resolution single-stage Orbitrap and a triple quadrupole mass spectrometer for quantitative analyses of drugs. Rapid Commun. Mass Spectrom. 2012, 26:499-509.
20. Fedorova G., Randak T., Lindberg R.H., Grabic R. Comparison of the quantitative performance of a Q-Exactive high-resolution mass spectrometer with that of a triple quadrupole tandem mass spectrometer for the analysis of illicit drugs in wastewater. Rapid Commun. Mass Spectrom. 2013, 27:1751-1762.
21. Lanckmans K., Sarre S., Smolders I., Michotte Y. Use of a structural analogue versus a stable isotope labeled internal standard for the quantification of angiotensin IV in rat brain dialysates using nano-liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2007, 21:1187-1195.
22. Bujak-Gizycka B., Madej J., Wolkow P.P., Olszanecki R., Drabik L., Rutowski J., Korbut R. Measurement of angiotensin metabolites in organ bath and cell culture experiments by liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS). J. Physiol. Pharmacol. 2007, 58:529-540.
23. Cui L., Nithipatikom K., Campbell W.B. Simultaneous analysis of angiotensin peptides by LC-MS and LC-MS/MS: metabolism by bovine adrenal endothelial cells. Anal. Biochem. 2007, 369:27-33.
24. Elased K.M., Cool D.R., Morris M. Novel mass spectrometric methods for evaluation of plasma angiotensin converting enzyme 1 and renin activity. Hypertension 2005, 46:953-959.
25. Hildebrand D., Merkel P., Eggers L.F., Schluter H. Proteolytic processing of angiotensin-I in human blood plasma. PLOS ONE 2013, 8:e64027.
26. Csanyi G., Gajda M., Franczyk-Zarow M., Kostogrys R., Gwozdz P., Mateuszuk L., Sternak M., Wojcik L., Zalewska T., Walski M., Chlopicki S. Functional alterations in endothelial NO, PGI(2) and EDHF pathways in aorta in ApoE/LDLR-/- mice. Prostaglandins Other Lipid Mediat. 2012, 98:107-115.
27. Daugherty A., Manning M.W., Cassis L.A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J. Clin. Invest. 2000, 105:1605-1612.
28. Wassmann S., Czech T., van Eickels M., Fleming I., Bohm M., Nickenig G. Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation 2004, 110:3062-3067.
29. Sugiyama F., Haraoka S., Watanabe T., Shiota N., Taniguchi K., Ueno Y., Tanimoto K., Murakami K., Fukamizu A., Yagami K. Acceleration of atherosclerotic lesions in transgenic mice with hypertension by the activated renin-angiotensin system. Lab. Invest. 1997, 76:835-842.
30. -/- mice. J. Lipid Res. 2013, 54:2255-2264.
31. Lu H., Balakrishnan A., Howatt D.A., Wu C., Charnigo R., Liau G., Cassis L.A., Daugherty A. Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis. Br. J. Pharmacol. 2012, 165:2000-2008.
32. Lu H., Rateri D.L., Feldman D.L., Jr R.J., Fukamizu A., Ishida J., Oesterling E.G., Cassis L.A., Daugherty A. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J. Clin. Invest. 2008, 118:984-993.
33. Seto S.W., Krishna S.M., Moran C.S., Liu D., Golledge J. Aliskiren limits abdominal aortic aneurysm, ventricular hypertrophy and atherosclerosis in an apolipoprotein-E-deficient mouse model. Clin. Sci. (Lond.) 2014, 127:123-134.
34. Guang C., Phillips R.D., Jiang B., Milani F. Three key proteases - angiotensin-I-converting enzyme (ACE), ACE2 and renin - within and beyond the renin-angiotensin system. Arch. Cardiovasc. Dis. 2012, 105:373-385.
35. Candido R., Jandeleit-Dahm K.A., Cao Z., Nesteroff S.P., Burns W.C., Twigg S.M., Dilley R.J., Cooper M.E., Allen T.J. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002, 106:246-253.
36. Sahara M., Ikutomi M., Morita T., Minami Y., Nakajima T., Hirata Y., Nagai R., Sata M. Deletion of angiotensin-converting enzyme 2 promotes the development of atherosclerosis and arterial neointima formation. Cardiovasc. Res. 2014, 101:236-246.
37. Thomas M.C., Pickering R.J., Tsorotes D., Koitka A., Sheehy K., Bernardi S., Toffoli B., Nguyen-Huu T.P., Head G.A., Fu Y., Chin-Dusting J., Cooper M.E., Tikellis C. Genetic ACE2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ. Res. 2010, 107:888-897.
38. Thatcher S.E., Zhang X., Howatt D.A., Lu H., Gurley S.B., Daugherty A., Cassis L.A. Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor-/- mice. Arterioscler. Thromb. Vasc. Biol. 2011, 31:758-765.
39. Jankowski V., Vanholder R., van der Giet M., Tolle M., Karadogan S., Gobom J., Furkert J., Oksche A., Krause E., Tran T.N., Tepel M., Schuchardt M., Schluter H., Wiedon A., Beyermann M., Bader M., Todiras M., Zidek W., Jankowski J. Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler. Thromb. Vasc. Biol. 2007, 27:297-302.
40. Ocaranza M.P., Michea L., Chiong M., Lagos C.F., Lavandero S., Jalil J.E. Recent insights and therapeutic perspectives of angiotensin-(1-9) in the cardiovascular system. Clin. Sci. (Lond.) 2014, 127:549-557.
41. Coutinho D.C., Foureaux G., Rodrigues K.D., Salles R.L., Moraes P.L., Murca T.M., De Maria M.L., Gomes E.R., Santos R.A., Guatimosim S., Ferreira A.J. Cardiovascular effects of angiotensin A: a novel peptide of the renin-angiotensin system. J. Renin Angiotensin Aldosterone Syst. 2014, 15:480-486.
42. Lautner R.Q., Villela D.C., Fraga-Silva R.A., Silva N., Verano-Braga T., Costa-Fraga F., Jankowski J., Jankowski V., Sousa F., Alzamora A., Soares E., Barbosa C., Kjeldsen F., Oliveira A., Braga J., Savergnini S., Maia G., Peluso A.B., Passos-Silva D., Ferreira A., Alves F., Martins A., Raizada M., Paula R., Motta-Santos D., Klempin F., Pimenta A., Alenina N., Sinisterra R., Bader M., Campagnole-Santos M.J., Santos R.A. Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ. Res. 2013, 112:1104-1111.